Dexcom Return on Equity

Dexcom (DXCM) currently reports a ROE of 38.14%. That is above the Healthcare sector average of 21.3%. Use the charts on this page to explore Dexcom's ROE history and peer comparisons.

Dexcom's ROE of 38.14% is higher than the Healthcare sector average of 21.3%. That is roughly 79.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Dexcom's current 38.14% should be judged against Healthcare norms (sector average: 21.3%) and against DXCM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 38.14%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.3%. From there, open related valuation or income-statement pages for Dexcom, and consider following DXCM for alerts when major investors trade the stock.

Dexcom is classified in the Healthcare sector. On ROE, it currently shows 38.14% versus a sector average near 21.3%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DXCM with unrelated industries.